Iloprost effects on phagocytes in patients suffering from ischaemic diseases: In vivo evidence for down-regulation of αMβ2 integrin

European Journal of Clinical Investigation

Volumn 26, Issue 10, 1996, Pages 860-866

  Mazzone, A ^a   Mazzucchelli, I ^a   Fossati, G ^a   Gritti, D ^a   Girola, S ^a   Canale, C ^a   Cusa, C ^a   Ricevuti, G ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Iloprost; Integrins; Peripheral artery occlusive disease; Phagocytes; Progressive systemic sclerosis

Indexed keywords

ACETYLSALICYLIC ACID; ILOPROST; INTEGRIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ISCHEMIA; MAJOR CLINICAL STUDY; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHAGOCYTE; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS;

EID: 0029851840     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2362.1996.tb02130.x     Document Type: Article

References (42)

1. Kannel WB, Anderson K, Wilson PWK. White blood cells and cardiovascular diseases. Results of Framingham study JAMA 1992;267:1253-6.
2. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med 1989;320:365-77.
3. Carlos TM, Harlan JM. Leukocyte endothelial adhesion molecules. Blood 1994;84:2068-101.
4. Wright SD, Weitz JI, Huang AJ, Levin SM, Silvestrein SC, Loike JD, Complement receptor type three (CD11b/CD18) of human polymorphonuclear leukocytes recognizes fibrinogen. Proc Natl Acad Sci USA 1988;85:7734-8.
5. Faint RW. Platelet neutrophil interactions; their significance. Blood Rev 1992;6:83-91.
6. Toothill VJ, Van Mourik JA, Niewenhuis HK, Metzelaar MJ, Pearson JD. Characterization of the enhanced adhesion of neutrophil leukocytes to thrombin-stimulated endothelial cells. J Immunol 1990;145:283-91.
7. Nathan C, Srimal S, Farber C. Cytokine-induced respiratory burst of human neutrophils: dependence on extracellular matrix proteins and CD11/CD18 integrins. J Cell Biol 1989;109:1341-52.
8. Wick G, Schett G, Amberger A, Kleindienst R, Xu Q. Is atherosclerosis an immunologically mediated disease? Immunol Today 1995;16:27-33.
9. Von Asmuth EJU, Van Der Linden CJ, Leeuwenberg JFT, Buurman WA. Involvement of the CD11b/CD18 integrin, but not of the endothelial cell adhesion molecules ELAM-1 and ICAM-1 in tumor necrosis factor-α-induced neutrophil toxicity. J Immunol 1991;142:3869-75.
10. Beekhuizen H, Blokland I, van Furth R. Cross-linking of CD14 molecules on monocytes results in a CD11/CD18 and ICAM-1 dependent adherence to cytokine-stimulated human endothelial cells. J Immunol 1993;150:950-9.
11. Neumann FJ, Waas W, Diehm C et al. Activation and decreased deformability of neutrophils after intermittent claudication. Circulation 1990;82:922-9.
12. Duplaa C, Couffinhal T, Labat L et al. Monocyte adherence to endothelial cells in patients with atherosclerosis:relationship with risk factors. Eur J Clin Invest 1993;23:474-9.
13. Ciuffetti G, Lombardini R, Paltriccia R, Santambrogio L, Mannarino E. Human leukocyte endothelial interactions in peripheral arterial occlusive disease. Eur J Clin Invest 1994; 24:65-8.
14. Altieri DC, Morrissey JH, Edgington TS. Adhesive receptor Mac-1 coordinates the activation of factor X on stimulated cells of monocytic and myeloid differentiation: an alternative initiation of the coagulation protease cascade. Proc Natl Acad Sci USA 1988;85:7462-71.
15. Renesto P, Hallbwachs-Mecarelli L, Nusbaum P, Lesavre P, Chignard M. Proteinase 3 a neutrophil proteinase with activity on platelets. J Immunol 1994;152:4612-7.
16. Simon DI, Ezratty AM, Francis SA, Rennke H, Loscalzo J. Fibrin (ogen) is internalized and degraded by activated human monocytoid cells via Mac-1 (CD11b/CD18): a nonplasmin fibrinolytic pathway. Blood 1993;82:2414-22.
17. Languino LR, Plescia J, Duperray A, et al. Fibrinogen mediates leukocyte adhesion to vascular endothelium through an ICAM-1 dependent pathway. Cell 1993;73:11423-34.
18. Ricevuti G, Mazzone A, Pasotti D, De Servi S, Specchia G. Role of granulocytes in endothelial injury in coronary heart disease in humans. Atherosclerosis 1991;91:1-14.
19. Bevilacqua MP, Nelson RM, Mannori G, Cecconi O. Endothelial leukocyte adhesion molecules in human disease. Annu Rev Med 1994;45:361-78.
20. Kuijpers TW, Tool ATJ, van der Schoot CE et al. Membrane surface antigen expression on neutrophils: a reappraisal of the use of surface markers for neutrophil activation. Blood 1991; 78:1105-11.
21. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994; 76:301-14.
22. Niculescu F, Rus HG, Vlaicu R. Activation of the human terminal complement pathway in atherosclerosis. Clin Immunol Immunopathol 1987;45:147-55.
23. Mulligan MS, Varani J, Warren JS et al. Role of β2 integrins of rat neutrophils in complement and oxygen radical-mediated acute inflammatory injury. J Immunol 1992;148:1847-57.
24. Mazzone A, De Servi S, Ricevuti et al. Increased neutrophil and monocyte adhesion molecules in unstable coronary artery disease. Circulation 1993;88:358-63.
25. Moncada S. Biological importance of prostacyclin. Br J Pharmac 1982;76:3-31.
26. Grant SM, Goa KL, Iloprost. Drugs 1992;43:889-924.
27. Nicolini FA, Mehta JL, Nichols W, Saldeen TGP, Grant M. Prostacyclin analogue Iloprost decreases trombolytic potential of tissue type plasminogen activator in canine coronary thrombosis. Circulation 1990;81:1115-22.
28. Belch JJF, Saniabadi AR, Forbes CD. Whole blood white cell aggregation: a novel technique. Thrombosis Res 1987;48:631-9.
29. Kanayama T, Kimura Y, Mizogami S. A new prostacyclin analog, KP-10614, inhibits platelet polymorphonuclear leukocyte interaction and limits experimental infarct size in rat heart. J Pharmacol Exp Ther 1993;266:344-9.
30. Riva CM, Morganroth ML, Marks RM, Todd RF, Ward PA. Iloprost inhibits activated human neutrophil (PMN) adherence to endothelial cells via increased cyclic AMP. Clin Res 1989;37:949A-54A.
31. European Working Group on Critical Leg Ischaemia. Second European Consensus Document on Chronic Critical Leg Ischaemia. Circulation 1991; 84 (suppl IV):IV-I IV-26.
32. Brando B, Sommaruga E. Nationwide quality control trial on lymphocyte immunophenotyping and flow cytometer performance in Italy. Cytometry 1993;14:294-306.
33. De Servi S, Mazzone A, Ricevuti G et al. Granulocyte activation after coronary angioplasty in humans. Circulation 1990;82:140-6.
34. Bellucci S, Kedra AW, Courmelle JM et al. Prolonged remission in Raynaud's phenomenon after prostacyclin infusion. Scand J Rheumatol 1986;15:392-8.
35. Nicolini FA, Mehta P, Lawson D, Mehta JL. Reduction in human neutrophil chemotaxis by the prostacyclin analogue iloprost. Thrombosis Res 1990;59:669-74.
36. Simpson PJ, Todd III RF, Fantone JC, Mickelson JK, Griffit JD, Lucchesi BR. Reduction of experimental canine myocardial reperfusion injury by a monoclonal antibody (anti-Mol, anti-CD11b) that inhibits leukocyte adhesion. J Clin Invest 1988;81:624-33.
37. Simpson PJ, Mickelson JK, Gallagher KP, Lucchesi BR. Iloprost inhibits neutrophil function in vitro and in vivo and limits experimental infarct size in canine heart. Circ Res 1987; 60:666-73.
38. Torley HI, Madhok R, Capell HA, Brouver RML, Maddison PJ. A double blind, randomized, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases. Ann Rheum Dis 1991;50:800-4.
39. Wigley FM, Sebold JR, Wise RA, McCloskey DA, Dole WP. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol 1992;19:1407-14.
40. Spiegel AM, Weinstein LS, Shenker A. Abnormalities in G-protein-coupled signal transduction pathway in human disease. J Clin Invest 1993;92:1119-25.
41. Theelen M, Dewald B, Baggiolini M. Neutrophils in signal transduction and activation of respiratory burst. Physiol Rev 1993;73:797-821.
42. Tong WJ, Gilman AG. Type specific regulation of adenylyl cyclase by G-protein b g subunits. Science 1991;254:1500-3.